# Xcell Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xcell-biosciences

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.xcellbio.com
- Total disclosed funding: $39M
- Latest round: Series B (Jan 19, 2022)
- Investors on record: 7

## About

Xcell Biosciences, Inc. is a biotechnology company focused on advanced cell therapy manufacturing, providing innovative solutions to enhance cancer immunotherapy and cell-based treatments.Founded in 2012, Xcell Biosciences, Inc. operates out of San Francisco, US, specializing in cell therapy manufacturing. The company was established by Brian Feth, who has a history of founding other ventures. Xcell has completed 6 deals, with the most recent funding round occurring on December 6, 2024, raising USD 1.4 mn in venture funding, which is also the total amount raised.Xcell Biosciences specializes in advanced cell therapy manufacturing, primarily through its innovative product offerings, which include the AVATAR series—AVATAR Foundry, AVATAR Odyssey, and AVATAR AI. The AVATAR Foundry serves as a scalable expansion platform aimed at producing cell therapies that can operate effectively within tumor microenvironments, enhancing the metabolic fitness of these therapies. AVATAR Odyssey is designed to improve cellular transduction processes, while AVATAR AI focuses on measuring the potency of cell therapy products. These offerings primarily target research institutions and biotechnology companies engaged in developing cancer immunotherapies and other cell-based treatments. Xcell Biosciences caters to markets across North America, Europe, and Asia-Pacific, ensuring a broad reach for its innovative solutions.Xcell Biosciences generates revenue through a business-to-business model, primarily engaging with research institutions and biotechnology firms that require specialized cell therapy manufacturing solutions. Transactions typically involve direct partnerships where clients utilize Xcell's AVATAR products in their research and development efforts, creating ongoing relationships centered around product supply and support. Specific pricing structures are established based on the nature of the services rendered, including potential subscription models for ongoing access to the AVATAR series and one-time fees for specific projects or product deployments. The flagship AVATAR Foundry and its associated services play a critical role in driving revenue by providing tailored solutions that enhance the efficacy of cell therapies in clinical applications.In December 2024, Xcell Biosciences, Inc. raised USD 1.4 mn in venture funding, which will be utilized to support the development and launch of new products, as well as explore expansion into new geographic markets. The company aims to enhance its product offerings by introducing updated versions of the AVATAR series and seeks to penetrate additional markets in Europe and Asia-Pacific by 2025.

## Funding rounds

- Series B, Jan 19, 2022, $12M — Viking Global Investors, Casdin Capital, HBM Genomics, LabCorp Ventures, Dynamk Capital, Formic Ventures
- Series B, Aug 11, 2021, $15M — HBM Partners, Viking Global Investors, Casdin Capital, LabCorp Ventures, Dynamk Capital, Formic Ventures
- Series A, Jan 24, 2017, $12M — HBM Genomics

## Investors

- HBM Genomics (https://capitalatlas.ai/funds/hbm-genomics) — Series A, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- LabCorp Ventures (https://capitalatlas.ai/funds/labcorp-ventures) — Series B
- Dynamk Capital (https://capitalatlas.ai/funds/dynamk-capital) — Series B
- Formic Ventures (https://capitalatlas.ai/funds/formic-ventures) — Series B